Effective CAR T-cell targeting of an MUC1 cleavage product
These results support that the combination of targeting MUC1*, the growth factor receptor form of MUC1, with a CAR T bearing the 1XX mutations in CD3ζ has therapeutic potential for the treatment of solid tumor cancers.
Authors
- Michael J. Nash (ORCID: https://orcid.org/0000-0002-4390-4531)
- Mark G. Carter
- Daniel M. Miller (ORCID: https://orcid.org/0000-0002-1460-0117)
- Cynthia Bamdad
- Jac-Leen S S Nash
- Kevin Yi (ORCID: https://orcid.org/0000-0003-3801-673X)
- Scott T. Moe
- Andrew K. Stewart
- David Smith (ORCID: https://orcid.org/0000-0001-9644-2353)
- Trevor J. Grant (ORCID: https://orcid.org/0000-0001-5478-1824)
- Naomi Miller
- Benoit J. Smagghe
- Jacy P. Marquez
- Laura L Agarkov
Institutions
- Minerva Biotechnologies (United States) (US)
- Mercy Health Foundation (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-010577
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09